Article
Immunology
Changju Qu, Rui Zou, Peng Wang, Qian Zhu, Liqing Kang, Nana Ping, Fan Xia, Hailing Liu, Danqing Kong, Lei Yu, Depei Wu, Zhengming Jin
Summary: This study demonstrates that CD19/CD22 dual-targeted CAR-T therapy, under a decitabine-containing lymphodepletion regimen, may be a safe and potent effective approach for patients with relapsed/refractory DLBCL.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Jhon R. Enterina, Susmita Sarkar, Laura Streith, Jaesoo Jung, Britni M. Arlian, Sarah J. Meyer, Hiromu Takematsu, Changchun Xiao, Troy A. Baldwin, Lars Nitschke, Mark J. Shlomchick, James C. Paulson, Matthew S. Macauley
Summary: Germinal centers are critical for antibody affinity maturation, and glycan remodeling plays a key role in maintaining B cells in the germinal center. Downregulation of CD22 ligands on B cells in the germinal center leads to increased apoptosis, reduced production of memory B cells and plasma cells, and delayed affinity maturation of antibodies. These defects are CD22 dependent.
Article
Multidisciplinary Sciences
Xin Yang, Qiuxia Yu, Hao Xu, Jianfeng Zhou
Summary: Treatment failure or relapse in CART therapy due to reduction in target antigen expression is a challenge. Epigenetic drug Chidamide can enhance CD22 expression on B-cell tumor cells, improving the efficacy of CD22 CART therapy by affecting protein distribution.
SCIENTIFIC REPORTS
(2021)
Article
Chemistry, Multidisciplinary
Senlian Hong, Chenhua Yu, Peng Wang, Yujie Shi, Weiqian Cao, Bo Cheng, Digantkumar G. Chapla, Yuanhui Ma, Jie Li, Emily Rodrigues, Yoshiki Narimatsu, John R. Yates, Xing Chen, Henrik Clausen, Kelly W. Moremen, Matthew Scott Macauley, James C. Paulson, Peng Wu
Summary: By modifying natural killer cells with glycan ligands targeting CD22, as well as selectins to promote trafficking to bone marrow, it is possible to achieve targeted killing of B lymphoma cells and improve cell trafficking to cancer cell locations, resulting in efficient suppression of lymphoma in vivo.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Article
Biotechnology & Applied Microbiology
Samanta Romina Zanetti, Talia Velasco-Hernandez, Francisco Gutierrez-Aguera, Victor M. Diaz, Paola Alejandra Romecin, Heleia Roca-Ho, Diego Sanchez-Martinez, Nestor Tirado, Matteo Libero Baroni, Paolo Petazzi, Raul Torres-Ruiz, Oscar Molina, Alex Bataller, Jose Luis Fuster, Paola Ballerini, Manel Juan, Irmela Jeremias, Clara Bueno, Pablo Menendez
Summary: CD19-directed CAR T cells have achieved impressive response rates in B-ALL, but relapse remains a challenge. A tandem CAR targeting both CD19 and CD22 showed similar efficacy as CD19-CAR in vitro and in vivo. It is worth exploring whether this approach can enhance leukemia eradication and reduce relapse rates.
Article
Immunology
Yao Sun, Yongfeng Su, Yizhi Wang, Na Liu, Yuhang Li, Jianlin Chen, Zhuoqing Qiao, Jingwen Niu, Jiangwei Hu, Bin Zhang, Hongmei Ning, Liangding Hu
Summary: The study presented a case of a patient with B-ALL who experienced extramedullary relapse after allogeneic stem cell transplantation and underwent multiple CAR-T cell therapies, including different variants of CD19 CAR-T cells. The patient achieved therapeutic responses after some of the treatments, demonstrating the potential efficacy of CAR-T cell therapy in relapsed B-ALL patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Medicinal
Horst Prescher, Astrid Schweizer, Martin Frank, Elena Kuhfeldt, Julia Ring, Lars Nitschke
Summary: The development of high affinity ligands for Siglecs is of significant interest due to their therapeutically relevant functions. This study introduces a new strategy for developing and designing Siglec ligands, using Siglec-2 (CD22) as an example, as disialyl-oligosaccharide mimetics. The study provides insights into the development and design of dimeric ligands with high affinity and avidity to cell surface-expressed CD22, as well as assay development, structure activity relationships, and biological data on calcium flux regulation in B-cells. State-of-the-art molecular dynamics simulations are used to model the binding modes of selected ligands, opening new perspectives for drug design efforts targeting Siglecs.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Hematology
John H. Baird, Matthew J. Frank, Juliana Craig, Shabnum Patel, Jay Y. Spiegel, Bita Sahaf, Jean S. Oak, Sheren F. Younes, Michael G. Ozawa, Eric Yang, Yasodha Natkunam, John Tamaresis, Zachary Ehlinger, Warren D. Reynolds, Sally Arai, Laura Johnston, Robert Lowsky, Everett Meyer, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Surbhi Sidana, Wen-Kai Weng, Kara L. Davis, Sneha Ramakrishna, Liora Schultz, Chelsea Mullins, Allison Jacob, Ilan Kirsch, Steven A. Feldman, Crystal L. Mackall, David B. Miklos, Lori Muffly
Summary: Despite poor prognosis in LBCL patients following CAR19 therapy failure, treatment with CAR22 in three consecutive patients showed promising results with all patients achieving complete remission and experiencing tolerable side effects, suggesting potential efficacy of CAR22 therapy in this population.
Article
Multidisciplinary Sciences
Samyuktha Ramesh, Soohyung Park, Wonpil Im, Melissa J. Call, Matthew E. Call
Summary: The B cell receptor (BCR) and T cell receptor (TCR) share a common core transmembrane (TM) structure, which is vital for optimal receptor assembly and stability in the cell membrane.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Biochemistry & Molecular Biology
June Ereno-Orbea, Xianglei Liu, Taylor Sicard, Iga Kucharska, Wei Li, Dorota Borovsky, Hong Cui, Yang Feng, Dimiter S. Dimitrov, Jean-Philippe Julien
Summary: CD22, a sialic acid-binding immunoglobulin-like lectin receptor expressed on B cells, serves as an inhibitory coreceptor and is a potential target for B-cell depletion in malignancies. Genetically modified T cells with m971-derived CARs have shown efficacy in targeting CD22, providing a successful immunotherapeutic approach.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Oncology
Yongxian Hu, Yali Zhou, Mingming Zhang, Wengang Ge, Yi Li, Li Yang, Guoqing Wei, Lu Han, Hao Wang, Shuhui Yu, Yi Chen, Yanbin Wang, Xiaohong He, Xingwang Zhang, Ming Gao, Jingjing Yang, Xiuju Li, Jiangtao Ren, He Huang
Summary: The study successfully developed CRISPR-edited universal CAR-T cells as a novel therapy for r/r ALL. Results showed that this therapy has a manageable safety profile and prominent antileukemia activity, providing an alternative treatment option for patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Thi Thuy Nguyen, Nguyen Thanh Nhu, Chia-Ling Chen, Chiou-Feng Lin
Summary: CD22/CD19 dual-targeting CAR-T-cell therapy has shown high efficacy with tolerable adverse effects in the management of relapsed/refractory B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The meta-analysis demonstrated that the overall response rate and complete remission rate were high, with favorable 1-year overall survival and progression-free survival. Treatment-related toxicity, such as cytokine release syndrome and neurotoxicity, occurred at similar rates in both ALL and NHL patients.
Review
Oncology
Lili Li, Luqin Wang, Qinhua Liu, Zhonghui Wu, Yulong Zhang, Ruixiang Xia
Summary: This study assessed the efficacy and safety of CD22 and CD19/CD22 CAR-T cell therapy for hematologic malignancies by summarizing existing evidence. The results showed that both CD22 and CD19/CD22 CAR-T immunotherapy demonstrated favorable efficacy and acceptable adverse events. Well-designed and large sample-sized clinical trials are needed for further validation.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Jing Zheng, Yao Xiao, Xue Q. Wu, Qiong Z. Xiao, Chun Feng, Kai B. Gao
Summary: A case report of a 33-year-old male with secondary CNSL who developed double CRS after CAR T-cell infusion was presented. The patient's symptoms were completely relieved after receiving appropriate treatment strategies, and achieved complete remission.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei
Summary: CD19-targeted CAR-T cell therapy has shown remarkable efficacy in treating B-cell malignancies, but CD19-negative relapse remains a significant challenge. CD22 serves as a potential alternative target for CD19 CAR-T cell-resistant patients, with therapies showing acceptable toxicities and promising efficacy.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)